source
- Inhibrx reports 9.6-month median PFS for OX40 agonist combo in phase 2 head-neck cancer trialInhibrx Biosciences presented updated data from its phase‑2 HexAgon study of the hexavalent OX40 agonist INBRX‑106 combined with Merck’s Keytruda in patients with untreated metastatic or unresectab…
- BMC Medical recalls 20,160 Luna G3 APAP devices over firmware defectOn July 15 2026 BMC Medical Co., Ltd. in Beijing reported to the FDA a recall of 20,160 Luna G3 APAP (Model LG3600) devices distributed in the United States because the installed firmware version G…